Loading
Uses organoids and functional genomics to find what pancreatic cancers depend on beyond KRAS.
Andrew J. Aguirre is an Institute Member at the Broad Institute of MIT and Harvard and a physician at Dana-Farber, working on pancreatic ductal adenocarcinoma and KRAS biology. He is known for leading real-time genomic profiling of advanced pancreatic cancer to enable precision medicine, the subject of his selected paper. His laboratory uses patient-derived organoids and functional genomics to find what pancreatic cancers depend on beyond KRAS. He now studies RAS-pathway dependencies and resistance to KRAS and RAS inhibitors.
| Title | Journal | Year |
|---|---|---|
| Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine | Cancer Discovery | 2018 |
A germline result is not the whole story: without loss of the second allele the tumour may not be repair-deficient, which is why tumour sequencing and, in trials, HRD signatures are read alongside.
Together with COMPASS it made sequencing at diagnosis of advanced disease a standard expectation, and it found the BRAF-deletion class that a hotspot test misses.
It is the reference multi-platform dataset and the reason a KRAS wild-type report is treated as a search for another driver rather than as an absence.
Shares Lustgarten Foundation, Pancreatic ductal adenocarcinoma.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
Shares Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine, Lustgarten Foundation, Patient-derived organoids, Pancreatic ductal adenocarcinoma.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, Pancreatic ductal adenocarcinoma.
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.